SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-018696
Filing Date
2023-11-13
Accepted
2023-11-13 08:10:42
Documents
82
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q kala-20230930x10q.htm   iXBRL 10-Q 2895977
2 EX-31.1 kala-20230930xex31d1.htm EX-31.1 15197
3 EX-31.2 kala-20230930xex31d2.htm EX-31.2 15171
4 EX-32.1 kala-20230930xex32d1.htm EX-32.1 6708
5 EX-32.2 kala-20230930xex32d2.htm EX-32.2 6840
  Complete submission text file 0001558370-23-018696.txt   10495932

Data Files

Seq Description Document Type Size
6 EX-101.SCH kala-20230930.xsd EX-101.SCH 73027
7 EX-101.CAL kala-20230930_cal.xml EX-101.CAL 63181
8 EX-101.DEF kala-20230930_def.xml EX-101.DEF 329142
9 EX-101.LAB kala-20230930_lab.xml EX-101.LAB 619307
10 EX-101.PRE kala-20230930_pre.xml EX-101.PRE 473091
76 EXTRACTED XBRL INSTANCE DOCUMENT kala-20230930x10q_htm.xml XML 1788614
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Filer) CIK: 0001479419 (see all company filings)

IRS No.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38150 | Film No.: 231395290
SIC: 2834 Pharmaceutical Preparations